Ironwood Pharmaceuticals ... (IRWD)
Ironwood Pharmaceuticals Statistics
Share Statistics
Ironwood Pharmaceuticals has 160.03M shares outstanding. The number of shares has increased by 2.24% in one year.
| Shares Outstanding | 160.03M |
| Shares Change (YoY) | 2.24% |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 155.19M |
| Failed to Deliver (FTD) Shares | 10 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 9.45M, so 5.9% of the outstanding shares have been sold short.
| Short Interest | 9.45M |
| Short % of Shares Out | 5.9% |
| Short % of Float | 6.08% |
| Short Ratio (days to cover) | 3.71 |
Valuation Ratios
The PE ratio is 5.41 and the forward PE ratio is 17.88. Ironwood Pharmaceuticals's PEG ratio is -0.05.
| PE Ratio | 5.41 |
| Forward PE | 17.88 |
| PS Ratio | 2.01 |
| Forward PS | 0.7 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Ironwood Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.4B.
| EV / Earnings | 18.37 |
| EV / Sales | 6.83 |
| EV / EBITDA | 25.32 |
| EV / EBIT | 25.32 |
| EV / FCF | 13.11 |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -2.87 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 50.67%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 50.67% |
| Revenue Per Employee | $1,316,142.32 |
| Profits Per Employee | $489,711.61 |
| Employee Count | 267 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -64.47M |
| Effective Tax Rate | -0.97 |
Stock Price Statistics
The stock price has increased by -83.18% in the last 52 weeks. The beta is 0.37, so Ironwood Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.37 |
| 52-Week Price Change | -83.18% |
| 50-Day Moving Average | 2.17 |
| 200-Day Moving Average | 4.17 |
| Relative Strength Index (RSI) | 35.88 |
| Average Volume (20 Days) | 3.31M |
Income Statement
In the last 12 months, Ironwood Pharmaceuticals had revenue of 351.41M and earned 130.75M in profits. Earnings per share was 0.82.
| Revenue | 351.41M |
| Gross Profit | 351.41M |
| Operating Income | 94.85M |
| Net Income | 130.75M |
| EBITDA | 94.85M |
| EBIT | 94.85M |
| Earnings Per Share (EPS) | 0.82 |
Balance Sheet
The company has 92.15M in cash and 715.54M in debt, giving a net cash position of -623.38M.
| Cash & Cash Equivalents | 92.15M |
| Total Debt | 715.54M |
| Net Cash | -623.38M |
| Retained Earnings | -1.7B |
| Total Assets | 389.52M |
| Working Capital | 129.22M |
Cash Flow
In the last 12 months, operating cash flow was 183.43M and capital expenditures -273K, giving a free cash flow of 183.15M.
| Operating Cash Flow | 183.43M |
| Capital Expenditures | -273K |
| Free Cash Flow | 183.15M |
| FCF Per Share | null |
Margins
Gross margin is 100%, with operating and profit margins of 26.99% and 37.21%.
| Gross Margin | 100% |
| Operating Margin | 26.99% |
| Pretax Margin | 18.86% |
| Profit Margin | 37.21% |
| EBITDA Margin | 26.99% |
| EBIT Margin | 26.99% |
| FCF Margin | 52.12% |
Dividends & Yields
IRWD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 56.55% |
| FCF Yield | 78.93% |
Analyst Forecast
The average price target for IRWD is $10, which is 589.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 589.7% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Apr 2, 2019. It was a forward split with a ratio of 597:500.
| Last Split Date | Apr 2, 2019 |
| Split Type | forward |
| Split Ratio | 597:500 |
Scores
| Altman Z-Score | -3.77 |
| Piotroski F-Score | 5 |